Wednesday, November 4, 2026

Back to the front page

The Buyback Shows Up (ESRT Q3 2026)

Empire State Realty Trust repurchased $85.8 million of shares at $4.56 each, using 1359 Broadway sale proceeds to fund buybacks and debt reduction.

From X

@StableBread

Fajasy on X

At ~$6.8M net of cash, Nubeva Technologies $NBVAF (TSXV: $NBVA) trades below every one of the five small ransomware-security deals I found with a disclosed price. That’s a CAD$13.0M market cap at CAD$0.185/share (70,173,783 × CAD$0.185), or $9.3M at 1.40 USD/CAD, with the $2.49M of cash and $12,262 of debt netted out. The $6.8M buys two granted patents, two pending applications, the unfinished AI decryptor builder, and a deployment agreement with what Nubeva calls a top-10 global bank, on $500,586 of FY2026 revenue. Here’s what larger security firms paid for five small companies that detect, stop, or recover from ransomware, per the buyers’ filings: → Smokescreen (June 2021): Zscaler $ZS paid ~$11.7M in cash for a startup that plants decoys to catch attackers. → TrapX Security (January 2022): Commvault $CVLT paid $18.65M in cash for an Israeli decoy-technology company. → Minerva Labs (March 2023): Rapid7 $RPD paid $34.6M for a 14-person Israeli startup selling anti-evasion and ransomware-prevention software. → Appranix (April 2024): Commvault paid $26.27M in cash and stock for a Boston startup that cuts the time to rebuild cloud applications after an attack. → Airgap Networks (April 2024): Zscaler paid $124.4M for an “early-stage” network-security company whose product it called a “ransomware kill switch.” For context, Commvault bought TrapX and Appranix as product lines already bringing in ~$3.2M and ~$2.4M a year. Rapid7 and Zscaler bought Minerva Labs and Airgap mainly for their technology. A buyer would be paying for Nubeva’s technology too, meaning four AI patents (assuming the last two come through), the key-capture agent, and a top-10 bank as a reference account (if the license customer renewed), not just ~$500K of revenue. Still, Nubeva’s revenue is a fifth or less of what TrapX and Appranix brought in, and 82% of its revenue comes from two customers, one of which may not have renewed. So I’d put a sale at the low end of these deals, $12-19M (Smokescreen to TrapX), or CAD$0.23-0.37/share, 1.3-2.0x from here. The ~$26M median (2.8x) is the more bullish upside case. If nothing works, two more years of burn leave $0.93-1.29M of cash, and adding the two granted patents and what’s left of the business gets shareholders $1.33-2.01M, or CAD$0.03-0.04/share, a 78-86% loss from CAD$0.185. In other words, CAD$0.185 sits ~45% of the way between the CAD$0.03-0.04 floor and a TrapX-size sale (CAD$0.37/share). If those are the only two outcomes, the market is pricing a sale as close to a coin flip.

New Ideas From The Road

Aurelion Research increased healthcare exposure and sees opportunities in banking and defense, alongside research on Alcoa, Nike, ONON and…

Site Centers (NYSE:SITC)

Site Centers' $3 per-share return-of-capital distribution and December delisting leave a discounted liquidation stub, with two properties…

Coupang: 3Q26 Business Recap

Coupang’s product-commerce growth rose 9% as data-leak effects fade, while management expects margins to return to pre-incident levels by…

update on Gartner

Gartner’s growth has stalled after federal contract losses and cautious commercial spending, raising questions about its competitive…

Recycle Bin

Used aircraft engines can be repurposed as gas turbines, easing data center power constraints while tightening aviation supply.

AMRZ · long

Amrize

Amrize (AMRZ) produces aggregates, cement and roofing materials across the US and Canada.

TWLO Q3 FY12/26 Earnings Review

Twilio's Q3 revenue rose 20% to $1.56 billion, but Q4 organic growth guidance fell to 11% to 12% and RPO declined 28%.

Namib Minerals: Research Flash

Namib Minerals accelerates Redwing’s restart, targeting first gold this month and a ramp from 338 ounces monthly to 835 ounces by Q2 2027.

Stevanato down 30%. Yikes.

Stevanato fell 30% after forecasting low-single-digit 2027 growth as lower Nexa syringe volumes from a GLP-1 customer offset solid Q3…

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

X accounts we follow

Every account on this site, hand-picked.

91 accounts

Investor letters we follow

359 firms

Sectors

Ordered by how often our editor reaches for them.